Seeking Alpha

NanoString Technologies soars after landing FDA 510k clearance for its Prosigna diagnostic test

  • NanoString Technologies (NSTG +41%) soars after receiving FDA 510(k) clearance for its Prosigna diagnostic test.
  • The test uses the gene expression profile of cells found in breast cancer tissue to assess a patient's risk of distant recurrence of disease.
  • Prosigna is the company's first FDA-approved in vitro diagnostic assay, and CEO Brad Gray notes the approval "marks a milestone for NanoString and is an important step forward in the treatment of breast cancer."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector